Valuation check: RENB's debt-to-equity ratio is -0.15, below the Healthcare sector average of 0.27.
Get informed when a big investor buys or sells
+ Follow-0.15
Debt-to-Equity ratio measures a company's financial leverage by comparing its total debt to shareholder equity. A lower D/E ratio generally indicates a more financially stable company with less risk.
Renovaro (RENB) currently reports a debt-to-equity ratio of -0.15. That is below the Healthcare sector average of 0.27. Use the charts on this page to explore Renovaro's debt-to-equity ratio history and peer comparisons.
Renovaro's debt-to-equity ratio of -0.15 is lower than the Healthcare sector average of 0.27. That is roughly 155.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The debt-to-equity ratio is a valuation multiple that relates Renovaro's market price to a fundamental measure such as earnings, sales, or book value. At -0.15, RENB can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current debt-to-equity ratio of -0.15, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 0.27. From there, open related valuation or income-statement pages for Renovaro, and consider following RENB for alerts when major investors trade the stock.
Renovaro is classified in the Healthcare sector. On debt-to-equity ratio, it currently shows -0.15 versus a sector average near 0.27. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RENB with unrelated industries.